Lawrence Steinman

TREATMENT OF NEUROINFLAMMATORY DISEASE

#2 | 2019-11-21

US20190350918A1

PPARy AGONIST FOR TREATMENT OF HUNTINGTON'S DISEASE

#3 | 2019-10-17

US20190315827A1

COMPOSITIONS AND METHODS FOR TREATMENT OF TYPE 1 DIABETES

#4 | 2019-06-20

US20190184007A1

AVOIDING NARCOLEPSY RISK IN INFLUENZA VACCINES

#5 | 2019-03-21

US20190083594A1

AQUAPORIN TOLERIZING VACCINES AND METHODS OF USE THEREOF

#6 | 2018-12-06

US20180346577A1

TREATMENT OF NEUROINFLAMMATORY DISEASE

#7 | 2018-09-27

US20180275145A1

Biomarkers for assessing subjects with multiple sclerosis

#8 | 2017-08-03

US20170216425A1

AVOIDING NARCOLEPSY RISK IN INFLUENZA VACCINES

#9 | 2017-07-13

US20170196893A1

TREATMENT OF INFLAMMATORY DEMYELINATING DISEASE WITH AGONISTS OF FARNESOID X RECEPTOR

#10 | 2017-01-26

US20170021000A1

Replacement gene tolerizing vectors and methods of use thereof

#11 | 2016-11-03

US20160317629A1

Aquaporin tolerizing vaccines and methods of use thereof

#12 | 2016-05-26

US20160146831A1

Antibody and Cytokine Biomarker Profiling for Determination of Patient Responsiveness

#13 | 2016-03-10

US20160068585A1

COMPOSITIONS AND METHODS FOR TREATMENT OF TYPE 1 DIABETES

#14 | 2015-09-24

US20150265691A1

Anthrose-based compositions and related methods

#15 | 2015-06-11

US20150157690A1

Amyloid beta peptides as therapy for multiple sclerosis

#16 | 2015-03-19

US20150079083A1

Alpha B-Crystallin as a Therapy for Ischemia or Inflammation

#17 | 2014-11-13

US20140335116A1

AVOIDING NARCOLEPSY RISK IN INFLUENZA VACCINES

#18 | 2014-10-16

US20140308244A1

Combination Therapy for Treatment of Inflammatory Demyelinating Disease

#19 | 2014-06-12

US20140161786A1

Therapeutic compositions and related methods

#20 | 2013-10-24

US20130281409A1

Myelin Sheath Fatty Acids that Resolve Neuroinflammation

#21 | 2013-05-23

US20130132112A1

SYSTEMS AND METHODS FOR CLINICAL PROTOCOL DEVELOPMENT

#22 | 2013-05-02

US20130108624A1

CRYPTIC GLYCAN MARKERS AND APPLICATIONS THEREOF

#23 | 2013-03-21

US20130071392A1

Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia

#24 | 2013-02-21

US20130046015A1

Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease

#25 | 2011-12-29

US20110318346A1

Alpha B-crystallin as a therapy for ischemia or inflammation

#26 | 2011-10-13

US20110250206A1

MARKERS FOR DETERMINATION OF PATIENT RESPONSIVENESS

#27 | 2011-10-06

US20110243893A1

Markers for determination of patient responsiveness

#28 | 2011-09-15

US20110223657A1

TRP/HIS exchange and kynurenin induced TRP transport

#29 | 2011-06-30

US20110160142A1

Alpha B-crystallin as a therapy for multiple sclerosis

#30 | 2010-07-15

US20100178292A1

CRYPTIC GLYCAN MARKERS AND APPLICATIONS THEREOF

#31 | 2010-05-27

US20100129376A1

Osteopontin Specific Antibodies and Methods of Use Thereof

#32 | 2009-12-24

US20090317357A1

Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents

#33 | 2009-11-12

US20090281170A1

POLYNUCLEOTIDE THERAPY

#34 | 2009-10-22

US20090264515A1

POLYNUCLEOTIDE THERAPY

#35 | 2009-06-09

US10302098

Polynucleotide therapy

#36 | 2009-02-26

US20090054251A1

Diagnosis of autoimmune disease

#37 | 2008-09-18

US20080227140A1

Trp/his exchange and kynurenine induced Trp transport

#38 | 2008-07-10

US20080166339A1

Inhibition of osteopontin for treatment of relapsing autoimmune disease

#39 | 2008-06-12

US20080138353A1

Alpha B-crystallin as a therapy for rheumatoid arthritis

#40 | 2008-01-31

US20080026485A1

Antibody profiling for determination of patient responsiveness

#41 | 2008-01-10

US20080009519A1

METHOD OF MODULATING T CELL FUNCTIONING

#42 | 2007-12-06

US20070280954A1

Nogo epitopic fragments for modulating immune response

#43 | 2007-01-25

US20070020691A1

Method of treating multiple sclerosis with phosphocholine containing lipids

#44 | 2005-11-24

US20050261215A1

Methods and immune modulatory nucleic acid compositions for preventing and treating disease

#45 | 2005-06-02

US20050119204A1